Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTX-080 in Advanced Solid Malignancies
NCT04485013Phase 1Active, not recruiting
- Sponsor
- Tizona Therapeutics
- Start
- Jul 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ttx-080 in cancer (11 arms), sponsored by Tizona Therapeutics. Primary endpoint: Objective Response Rate at 48 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
ttx-080
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04485013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485013.